NCT06657690View on ClinicalTrials.gov

Irinotecan Liposome Combined with S-1 in PD-1/L1 Inhibitor Refractory Recurrent or Metastatic NPC

PHASE2RecruitingINTERVENTIONAL
Enrollment

56

Participants

Timeline

Start Date

November 1, 2024

Primary Completion Date

October 31, 2026

Study Completion Date

October 31, 2027

Conditions
Recurrent or Metastatic Nasopharyngeal Carcinoma
Interventions
DRUG

Irinotecan liposome

Irinotecan liposome injection, 50mg/m2, D1、D15, ivgtt, Q4w.

DRUG

S-1

S-1, D1-D14, BID, p.o., Q4w (BSA \< 1.25 m2, 40 mg/dose; 1.25 m2 ⩽ BSA \< 1.5 m2, 50 mg/dose; BSA ⩾ 1.5 m2, 60mg/dose).

Trial Locations (1)

519000

RECRUITING

Fifth affiliated hosptial of Sun-yat Sen university, Zhuhai

All Listed Sponsors
lead

Sun Yat-sen University

OTHER